Compare JPMorgan Chase & Co (JPM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs GeneDx Holdings Corp — how do they compare? JPMorgan Chase & Co trades at $342.3 (market cap $900.78B), while GeneDx Holdings Corp trades at $60.64 (market cap $1.80B). The key difference: JPMorgan Chase & Co is far larger — about 500.4× GeneDx Holdings Corp's market cap, and JPMorgan Chase & Co pays a 1.77% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| JPM | WGS | |
|---|---|---|
Market Cap | $900.78B | $1.80B |
Volume | 10,479,943 | — |
Sector | Financials | Technology |
52-Week High | $346.91 | $167.51 |
52-Week Low | $282.84 | $34.51 |
Dividend Yield | 1.77% | — |
Enterprise Value | — | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase & Co. (JPM) trades at $342.57, up 0.43% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 14.52 and net income margin of 33.4%, though Q4 2025 EPS missed expectations. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 2026 earnings, with analyst consensus leaning bullish.
JPM offers upside to the $372.73 consensus price target, driven by earnings beats and sector resilience, but faces risks from geopolitical tensions, cybersecurity threats, and volatile cash flows. Investors should weigh solid profitability against macroeconomic headwinds highlighted in recent shareholder communications.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
